These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33187767)

  • 21. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
    Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
    Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.
    Arguedas A; Soley C; Abdelnour A; Sales V; Lindert K; Della Cioppa G; Clemens R;
    Hum Vaccin; 2011 Jan; 7(1):58-66. PubMed ID: 21285531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mode of action of adjuvants: implications for vaccine safety and design.
    Mastelic B; Ahmed S; Egan WM; Del Giudice G; Golding H; Gust I; Neels P; Reed SG; Sheets RL; Siegrist CA; Lambert PH
    Biologicals; 2010 Sep; 38(5):594-601. PubMed ID: 20659806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults.
    Leroux-Roels G; Van Damme P; Haazen W; Shakib S; Caubet M; Aris E; Devaster JM; Peeters M
    Vaccine; 2016 Jun; 34(27):3156-3163. PubMed ID: 27133877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
    Burny W; Marchant A; Hervé C; Callegaro A; Caubet M; Fissette L; Gheyle L; Legrand C; Ndour C; Tavares Da Silva F; van der Most R; Willems F; Didierlaurent AM; Yarzabal J;
    Vaccine; 2019 Mar; 37(14):2004-2015. PubMed ID: 30850240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study.
    Susarla SK; Gupta M; Mantan M; Dhongade R; Bhave S; Das RK; Ray RK; Ramesh Babu T; Ravi MD; Krishnamurthy B; James S; Sandhya G; Satish M; Sahoo DP
    Vaccine; 2019 Aug; 37(36):5452-5459. PubMed ID: 31331773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults.
    Baay M; Bollaerts K; Verstraeten T
    Vaccine; 2018 Jul; 36(29):4207-4214. PubMed ID: 29885773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.
    Chen WH; Neuzil KM; Boyce CR; Pasetti MF; Reymann MK; Martellet L; Hosken N; LaForce FM; Dhere RM; Pisal SS; Chaudhari A; Kulkarni PS; Borrow R; Findlow H; Brown V; McDonough ML; Dally L; Alderson MR
    Lancet Infect Dis; 2018 Oct; 18(10):1088-1096. PubMed ID: 30120069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
    Bona G; Castiglia P; Zoppi G; de Martino M; Tasciotti A; D'Agostino D; Han L; Smolenov I
    Vaccine; 2016 Jun; 34(29):3363-70. PubMed ID: 27181507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologicals: test procedures available to assess components and products, with limitations.
    Lee AM
    Rev Sci Tech; 1995 Dec; 14(4):1073-82. PubMed ID: 8639947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
    Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
    Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
    Lim FS; Phua KB; Lee BW; Quak SH; Teoh YL; Ramakrishnan G; Han HH; Van Der Meeren O; Jacquets JM; Bock HL
    Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):138-47. PubMed ID: 21323176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
    Tapia MD; Sow SO; Ndiaye BP; Mbaye KD; Thiongane A; Ndour CT; Mboup S; Ake JA; Keshinro B; Akintunde GA; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Hogrefe WR; Günther S; Naficy A; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
    Lancet Infect Dis; 2020 Jun; 20(6):707-718. PubMed ID: 32199491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium.
    Weiner J; Lewis DJM; Maertzdorf J; Mollenkopf HJ; Bodinham C; Pizzoferro K; Linley C; Greenwood A; Mantovani A; Bottazzi B; Denoel P; Leroux-Roels G; Kester KE; Jonsdottir I; van den Berg R; Kaufmann SHE; Del Giudice G
    Sci Rep; 2019 Dec; 9(1):20362. PubMed ID: 31889148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Predictive Model of Vaccine Reactogenicity Using Data from an In Vitro Human Innate Immunity Assay System.
    Pullen RH; Sassano E; Agrawal P; Escobar J; Chehtane M; Schanen B; Drake DR; Luna E; Brennan RJ
    J Immunol; 2024 Mar; 212(5):904-916. PubMed ID: 38276072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the individual and the community in the research, development, and use of biologicals with criteria for guidelines: a memorandum.
    Bull World Health Organ; 1976; 54(6):645-55. PubMed ID: 1088511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.